enGene Holdings Inc. Common Stock

ENGN · NASDAQ · Healthcare / Biotechnology

2.41USD+0.13 (+5.70%)

Price History

Full chart

Market Stats

Previous Close2.28

Open2.41

Day Range2.17 – 2.51

52-Week Range1.40 – 12.25

Volume3.70M

Market Cap128.67M

P/E (TTM)0.00

Forward P/E0.00

EPS-2.07

Dividend Yield0.00%

Beta-0.27

50-Day Avg1.84

200-Day Avg5.27

About

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Ronald H. W. Cooper
Employees81
Headquarters4868 Rue Levy, Montreal, QC, Canada, H4R 2P1, USA
Websitehttps://www.engene.com

Leadership

Mr. Ronald H. W. CooperPresident, CEO & Director · b. 1963
Dr. William J. Grossman M.D., Ph.D.Interim Chief Medical Officer & Director · b. 1970
Dr. Anthony T. Cheung Ph.D.Co-Founder & Chief Scientific Officer · b. 1972
Ms. Kathleen RichtonSenior VP of Finance, Principal Accounting & Financial Officer and Controller · b. 1978
Ms. Joan ConnollyChief Technology Officer · b. 1970
Ms. Tara Place M.B.A.Senior VP of Human Resources
Mr. Matthew BoydChief Regulatory Officer · b. 1974
Ms. Jill BuckChief Development Officer · b. 1974
Ms. Amy PottChief Global Commercialization Officer · b. 1976

Financials

Income Statement

Currency: USD	2020-10-31	2021-10-31	2022-10-31	2023-10-31	2024-10-31	2025-10-31
Total Revenue	0	0	0	0	0	0
Cost of Revenue	-	-	-	175.00K	323.00K	509.00K
Gross Profit	-	-	-	-175.00K	-323.00K	-509.00K
Operating Expense	-	-	-	25.89M	61.97M	122.66M
Operating Income	-13.85M	-15.87M	-19.43M	-26.06M	-62.30M	-123.17M
EBITDA	-12.90M	-18.14M	-22.78M	-94.77M	-52.04M	-113.80M
Net Income	-15.07M	-23.44M	-24.46M	-99.92M	-55.14M	-117.30M
R&D	10.61M	12.46M	15.47M	16.46M	38.31M	94.48M
Interest Expense	3.70M	5.02M	1.42M	4.95M	2.80M	2.99M

Balance Sheet

Currency: USD	2020-10-31	2021-10-31	2022-10-31	2023-10-31	2024-10-31	2025-10-31
Total Assets	-	131.45M	132.04M	86.96M	311.17M	221.47M
Total Liabilities	-	4.05M	4.62M	14.47M	38.56M	53.76M
Total Equity	-	127.39M	127.42M	72.49M	272.61M	167.71M
Cash	-	1.07M	314.15K	81.52M	173.00M	50.15M
Total Debt	-	4.16M	32.11M	9.78M	25.02M	31.80M
Net Debt	-	-1.07M	-314.15K	-71.74M	-147.98M	-18.36M

Cash Flow

Currency: USD	2020-10-31	2021-10-31	2022-10-31	2023-10-31	2024-10-31	2025-10-31
Operating Cash Flow	-13.06M	-15.98M	-17.59M	-24.74M	-48.28M	-99.24M
Investing Cash Flow	-192.00K	-247.00K	-153.00K	-318.00K	-125.95M	-25.14M
Financing Cash Flow	12.85M	22.52M	27.97M	86.15M	265.72M	1.52M
Capital Expenditure	192.00K	248.00K	153.00K	318.00K	925.00K	1.49M
Free Cash Flow	-13.25M	-16.23M	-17.75M	-25.06M	-49.21M	-100.72M
FCF to OCF	101.47%	101.55%	100.87%	101.29%	101.92%	101.50%

Earnings

Report Date	Jan 24, 2022	Apr 14, 2022	May 13, 2022	Aug 11, 2022	Nov 10, 2022	Mar 30, 2023	Jun 30, 2023	Jul 31, 2023	Jan 3, 2024	Mar 11, 2024	Jun 14, 2024	Sep 10, 2024	Dec 19, 2024	Mar 10, 2025	Jun 12, 2025	Sep 11, 2025	Dec 22, 2025	Mar 9, 2026	Jun 15, 2026	Sep 8, 2026
EPS Estimate	0.00	-	-	-	-	-	-	-	-	-0.47	-0.27	-0.35	-0.36	-0.37	-0.48	-0.51	-0.58	-0.57	-0.48	-0.44
EPS Actual	0.00	-0.01	-0.03	-0.02	0.04	0.04	-0.17	-0.00	-4.51	-0.46	-0.38	-0.32	-0.34	-0.48	-0.51	-0.57	-0.73	-0.44	-0.43	0.47
Surprise	-	-	-	-	-	-	-	-	-	2.13%	-40.74%	8.57%	5.56%	-29.73%	-6.25%	-11.76%	-25.86%	23.32%	10.42%	206.82%
Timing	-	-	-	-	-	-	-	-	-	After-hours	Pre-market	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	-	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap128.67M

Enterprise Value-98.35M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book0.58

EPS-2.07

Book Value3.44

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-135.93M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-60.50%

Return on Assets-32.00%

Shares Outstanding67.02M

Shares Float32.76M

Beta-0.27

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 10 analystsTarget 3.29

Strong Buy
4
Buy
5
Hold
1

Ownership Breakdown

Institutions: 84.10%
Insiders: 0.10%
Retail / Other: 15.80%

Top Institutional Holders

BML Capital Management LLC
6.67M9.95%
Siren, L.L.C.
5.25M7.84%
Perceptive Advisors LLC
4.82M7.20%
BRAIDWELL LP
2.46M3.67%
Nextech Invest, Ltd.
2.32M3.47%
Franklin Templeton Inc
1.31M1.96%
Polar Capital Holdings PLC
1.22M1.83%
Balyasny Asset Management LLC
1.15M1.71%
Peapod Lane Capital LLC
1.10M1.64%
Millennium Management LLC
966.63K1.44%
Omega Fund Management LLC
876.36K1.31%
SR ONE CAPITAL MANAGEMENT, LP
747.75K1.12%
Citadel Advisors Llc
717.69K1.07%
Affinity Asset Advisors, LLC
600.00K0.90%
Quadrature Capital Limited
478.07K0.71%
Eversept Partners, LP
469.58K0.70%
Kynam Capital Management, LP
457.86K0.68%
Privium Fund Management B.V.
352.09K0.53%
Marshall Wace Asset Management Ltd
343.93K0.51%
Monashee Investment Management LLC
320.00K0.48%